We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA Pushes Back PDUFA Date on Titan’s Opioid Dependence NDA
Novartis Secures Breakthrough Therapy Designation for AML Candidate
Germany Rebuffs Cholesterol Drug
Shionogi’s Naldemedine Meets Primary Endpoint in Phase 3
FDA Awards Nivalis Cystic Fibrosis Candidate Fast Track Status